Welcome to our dedicated page for Iridex news (Ticker: IRIX), a resource for investors and traders seeking the latest updates and insights on Iridex stock.
Iridex Corporation (IRIX) delivers innovative laser-based medical systems for ophthalmology, specializing in noninvasive treatments for glaucoma and retinal diseases. This news hub provides investors and healthcare professionals with timely updates on product developments, financial performance, and clinical advancements.
Access authoritative information about IRIX's proprietary MicroPulse technology, regulatory milestones, and global market initiatives. Our curated collection features earnings announcements, partnership updates, and clinical study results – all essential for tracking the company's position in medical device innovation.
Discover updates across key categories including new product clearances, international distribution expansions, and peer-reviewed research findings. Content is regularly updated to reflect IRIX's progress in enhancing ophthalmic care through advanced laser systems and procedural tools.
Bookmark this page for streamlined access to verified Iridex developments. Combine strategic business insights with technical expertise through our comprehensive news repository – your primary source for monitoring this medical technology leader's trajectory.
Iridex Corporation (Nasdaq: IRIX) reported strong financial results for Q1 2021, achieving record revenue of $12.0 million, up 33% from $9.0 million year-over-year. The growth was driven by a strategic collaboration with Topcon, contributing $19.5 million in funds and robust sales of new products. Cyclo G6 product sales reached $3.3 million, marking a 15% increase. Despite a net loss of $2.0 million, the company holds $28 million in cash, expecting full-year revenue of $48 million to $51 million, representing growth of 32%-40%.
Iridex Corporation (NASDAQ: IRIX) announced that it will release its financial results for Q1 2021 on May 11, 2021, after trading hours. A conference call will follow at 2:00 p.m. PT / 5:00 p.m. ET. The call can be accessed by domestic callers at (844) 707-0665 and international callers at (703) 326-3030, using conference ID: 1282162. Iridex specializes in innovative ophthalmic laser-based medical products for glaucoma and retinal diseases, utilizing its proprietary MicroPulse® technology to deliver effective treatments worldwide.
Iridex Corporation (Nasdaq: IRIX) reported a 5% increase in fourth-quarter revenue to $12.3 million year-over-year, driven by an 8% growth in U.S. Cyclo G6 probe sales. Gross margin improved to 45.4%, aided by higher selling prices and reduced operating expenses, which fell by 9% to $5.9 million. The company experienced a reduced net loss of $179,000. For 2020, total revenue decreased to $36.3 million due to COVID-19 impacts, while the net loss was cut to $6.3 million. Guidance for 2021 remains uncertain due to ongoing COVID challenges and the new collaboration with Topcon Corporation.
Iridex Corporation (NASDAQ: IRIX) announced the completion of a significant transaction with Topcon Corporation, involving a $10 million equity investment and exclusive distribution rights for its products in key regions. The total deal nets Iridex $19.5 million, providing capital for strategic growth in glaucoma and retina product lines. CEO David Bruce highlighted the partnership's potential to enhance global patient care and physician support. The transaction was initially revealed on March 2, 2021.
Iridex Corporation (NASDAQ: IRIX) will release its financial results for Q4 and full year 2020 after trading on March 22, 2021. A conference call with management is scheduled for 2:00 p.m. PT / 5:00 p.m. ET, which investors can access by calling (844) 707-0665 domestically or (703) 326-3030 internationally, using conference ID: 1137827. The event will also be webcast live and archived on Iridex's website. The company specializes in ophthalmic laser-based medical products for glaucoma and retinal diseases.
Iridex (NASDAQ: IRIX) announced a strategic collaboration with Topcon Corporation, securing $19.5 million in cash to fuel growth in glaucoma and retinal disease treatments. This partnership includes exclusive distribution rights for Iridex's products in key markets and a 10.4% equity stake acquisition by Topcon. Iridex will also gain the PASCAL® product line from Topcon, enhancing its portfolio. The collaboration aims to improve market penetration and operational efficiencies. A conference call is scheduled for March 2, 2021, to discuss the partnership further.
IRIDEX Corporation (Nasdaq: IRIX) announced preliminary unaudited results for Q4 and the full year 2020. Q4 revenue is projected at $12.2-$12.4 million, an increase from $11.8 million in Q4 2019. Full-year revenue is expected to be $36.2-$36.4 million, down 16% from $43.4 million in 2019. The company sold 13,500 Cyclo G6® probes in Q4, reflecting an 8% increase in U.S. sales. However, sales of Cyclo G6 Glaucoma Laser Systems decreased to 56 units. Cash burn was $0.3 million in Q4 and $1.0 million for the year, signaling effective expense management despite COVID-19 impacts.
IRIDEX Corporation (NASDAQ: IRIX) has announced that its MicroPulse Transscleral Laser Therapy (TLT) is included in the European Glaucoma Society's (EGS) guidelines for glaucoma diagnosis and management. Presented at the EGS Annual Meeting, nine studies highlighted the procedure's safety, effectiveness, and versatility for various types of glaucoma. MicroPulse TLT has treated over 140,000 patients globally and shows promise in significantly reducing intraocular pressure. The increasing recognition and adoption of this non-incisional therapy could positively impact IRIDEX's market position.
IRIDEX Corporation (Nasdaq: IRIX) reported third-quarter financial results for the period ending September 26, 2020. Total revenue was $8.8 million, down 17% year-over-year but up 42% sequentially. The company sold 11,400 Cyclo G6 probes, marking a 6% increase from the prior year and a 44% increase from the previous quarter. However, sales of Cyclo G6 Glaucoma Laser Systems fell to 37 units from 82 a year ago due to COVID-related deferrals. The company ended the quarter with $11.9 million in cash and a reduced net loss of $1.7 million.
IRIDEX Corporation (Nasdaq: IRIX) announced its participation in the Stifel Virtual Healthcare Conference on November 17, 2020, at 4:40 pm ET. David I. Bruce, the CEO, will present, and interested individuals can access the live and archived webcast via the IRIDEX website.
IRIDEX specializes in laser-based medical systems for ophthalmology, notably using MicroPulse technology for treating conditions like glaucoma and diabetic macular edema. Its products are available in over 100 countries.
